

1 Report:

2

3 **Fungi of the order Mucorales express a “sealing-
4 only” tRNA ligase**

5

6

7

8 Khondakar Sayef Ahammed and Ambro van Hoof^{*}

9

10

11

12 Department of Microbiology and Molecular Genetics.

13 UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences.

14 University of Texas Health Science Center at Houston.

15

16 * Correspondence to ambro.van.hoof@uth.tmc.edu

17

18 Running title: A sealing-only tRNA ligase in Mucorales fungi

19 Keywords: *TRL1*, tRNA splicing, antifungal target

20

21

22 **Abstract**

23

24 Some eukaryotic pre-tRNAs contain an intron that is removed by a dedicated set of enzymes.
25 Intron-containing pre-tRNAs are cleaved by tRNA splicing endonuclease (TSEN), followed by
26 ligation of the two exons and release of the intron. Fungi use a “heal and seal” pathway that
27 requires three distinct catalytic domains of the tRNA ligase enzyme, Trl1. In contrast, humans use
28 a “direct ligation” pathway carried out by RTCB, an enzyme completely unrelated to Trl1. Because
29 of these mechanistic differences, Trl1 has been proposed as a promising drug target for fungal
30 infections. To validate Trl1 as a broad-spectrum drug target, we show that fungi from three
31 different phyla contain Trl1 orthologs with all three domains. This includes the major invasive
32 human fungal pathogens, and these proteins each can functionally replace yeast Trl1. In contrast,
33 species from the order Mucorales, including the pathogens *Rhizopus arrhizus* and *Mucor*
34 *circinelloides*, contain an atypical Trl1 that contains the sealing domain, but lack both healing
35 domains. Although these species contain fewer tRNA introns than other pathogenic fungi, they
36 still require splicing to decode three of the 61 sense codons. These sealing-only Trl1 orthologs
37 can functionally complement defects in the corresponding domain of yeast Trl1 and use a
38 conserved catalytic lysine residue. We conclude that Mucorales use a sealing-only enzyme
39 together with unidentified non-orthologous healing enzymes for their heal and seal pathway. This
40 implies that drugs that target the sealing activity are more likely to be broader-spectrum
41 antifungals than drugs that target the healing domains.

42

43 **Introduction**

44 In all eukaryotes, a subset of tRNA precursors contains introns that are removed by a specialized
45 set of tRNA splicing enzymes (Popow et al. 2012; Phizicky and Hopper 2023). In contrast to
46 spliceosomal splicing of mRNAs and other non-coding RNAs, tRNA splicing is a protein-mediated
47 process initiated by cleavage of the pre-tRNAs by the tRNA splicing endonuclease complex
48 (TSEN) (Peebles et al. 1979; Hayne et al. 2023). TSEN generates a 5' exon that ends with a 2' 3'
49 cyclic phosphate and a 3' exon with a 5' hydroxyl in a catalytic mechanism that is similar to that
50 used by RNase A (Peebles et al. 1983). This initial step of tRNA splicing appears conserved in all
51 eukaryotes, but two distinct mechanisms are used for the subsequent ligation step of two tRNA
52 halves (5' and 3' exons) (Greer et al. 1983; Phizicky et al. 1986).

53 Most Metazoa and some protozoa use a “direct ligation” mechanism to join the tRNA exons, which
54 is carried out by RTCB enzymes. RTCB uses a catalytic histidine residue to transfer GMP onto
55 the 3' end of the 5' exon, generating an activated exon that can then be ligated to the 3' exon
56 (Chakravarty et al. 2012; Englert et al. 2012; Desai et al. 2013; Jacewicz et al. 2022). RTCB has
57 been implicated in tRNA splicing in humans, *Caenorhabditis elegans*, and *Drosophila*
58 *melanogaster*, and homologs of RTCB are encoded in most metazoan genomes (Popow et al.
59 2011; Kosmaczewski et al. 2014; Lu et al. 2014; Nandy et al. 2017). Although bacteria do not
60 have tRNA introns (except rare group I self-splicing introns), some bacteria, including *Escherichia*
61 *coli* also contain RTCB homologs that instead function in tRNA repair (Tanaka et al. 2011; Tanaka
62 and Shuman 2011; Chen and Wolin 2023).

63 In contrast, most fungi and plants and some other protozoa use a “heal and seal” mechanism
64 carried out by the multifunctional enzyme Trl1 to join tRNA exons (Konarska et al. 1981; Greer et
65 al. 1983; Phizicky et al. 1986; Abelson et al. 1998; Sawaya et al. 2003; Lopes et al. 2015; Phizicky
66 and Hopper 2023). The heal and seal mechanism involves three distinct steps that are carried out
67 by three different catalytic domains of Trl1. In one “healing” reaction, the cyclic phosphodiesterase
68 (CPD) domain converts the 2'3' cyclic phosphate of the 5' exon to a 3'-OH, 2' PO₄ end. In a second
69 “healing” reaction, the kinase domain converts the 5' hydroxyl of the 3' exon to a 5' phosphate.
70 Finally, in the “sealing” reaction, the ligase domain uses a catalytic lysine residue to transfer AMP
71 onto the 3' exon, which activates it for ligation to the 5' exon (Wang et al. 2006; Banerjee et al.
72 2019). Thus, both the catalytic residue (His vs. Lys) that carries out activation, as well as the exon
73 (5' vs. 3') that is activated, differ between the direct ligation and heal and seal pathways. The heal
74 and seal mechanism generates an initial ligation product with a 2' phosphate at the exon junction,
75 which is removed by tRNA 2'-phosphotransferase (Tpt1) (Spinelli et al. 1997; Steiger et al. 2001).
76 The bacteriophage T4 encodes a polynucleotide kinase (PNK) and RNA ligase (Rnl1) that are
77 widely used in molecular biology but whose normal role is in a related but distinct tRNA repair
78 pathway (Amitsur et al. 1987; Shuman 2023). The T4 pathway does not involve a 2'PO₄
79 intermediate or a Tpt1. Strikingly, these distinct pathways are interchangeable and the yeast *TRL1*
80 gene can be replaced by either *E. coli* RtcB or T4 PNK and T4 Rnl1 (Schwer et al. 2004; Tanaka
81 et al. 2011).

82 Both RTCB and Trl1 have an additional function in the splicing of a single mRNA during unfolded
83 protein response (UPR) (Sidrauski et al. 1996; Gonzalez et al. 1999; Mori 2009). During
84 endoplasmic reticulum (ER) stress, the endonuclease Ire1 cleaves the *Saccharomyces cerevisiae*
85 (hereafter “yeast”) *HAC1* and human *XBP1* mRNAs. Similar to TSEN, Ire1 also generates a 5'
86 exon that ends with a 2' 3' cyclic phosphate and a 3' exon with a 5' hydroxyl, and these exons are
87 ligated by RTCB and Trl1, in Metazoa and Fungi, respectively, using the same mechanism used
88 for tRNA ligation.

89 The fungal tRNA exon ligation mechanism has been proposed as an attractive target for anti-
90 fungal drug development for several reasons (Wang and Shuman 2005; Tanaka et al. 2011;

91 Chakravarty et al. 2012; Remus et al. 2016): (i) tRNA splicing is essential in all eukaryotes.
92 Without it, eukaryotes cannot generate a complete set of tRNAs and cannot translate a subset of
93 codons. (ii) Fungi are relatively closely related to humans and there are very few fundamental
94 differences in their biochemical pathways. As a result, there are very few genes that are essential
95 in fungi but that do not have a close homolog in the human genome (Braun et al. 2005; Liu et al.
96 2006). (iii) The biochemical mechanism of tRNA exon ligation by fungal Trl1 is distinct from the
97 metazoan enzyme RTCB. (iv) All three domains of Trl1 are required for its function in tRNA ligation
98 and cell survival in the model fungus *Saccharomyces cerevisiae* (Sawaya et al. 2003; Wang and
99 Shuman 2005; Wang et al. 2006). Therefore, a Trl1 inhibitor that targets any of the three essential
100 domains is a potential anti-fungal drug candidate.

101 Novel antifungal drugs are urgently needed. There are only three classes of approved antifungal
102 drugs for invasive disease, and resistance to these drugs limits their use. The CDC considers *C.
103 auris* as one of six urgent threats of antimicrobial resistant pathogens, other drug-resistant
104 *Candida* species as a serious threat, and azole-resistant *Aspergillus* as a watch list threat
105 (<https://www.cdc.gov/drugresistance/biggest-threats.html>). In the US, fungal disease are
106 responsible for seven billion dollars in annual health care costs (Benedict et al. 2019) and 3% of
107 all hospitalized patients receive an antifungal drug (Vallabhaneni et al. 2018). The WHO issued a
108 report last year calling for increased research into 19 fungi that represent the greatest threat to
109 human health (<https://www.who.int/news-room/detail/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi>). Fungal infections alarmingly have become one of the major global health
110 problems among immunocompromised individuals. Among several types of fungal infections,
111 invasive and pulmonary fungal diseases such as candidiasis, aspergillosis, cryptococcal
112 meningitis, pneumocystis pneumonia, histoplasmosis, and mucormycosis are leading causes of
113 morbidity and mortality worldwide (Garber 2001; von Lilienfeld-Toal et al. 2019; Kainz et al. 2020;
114 Reddy et al. 2022). In addition, patients with existing health conditions such as HIV, cancer, and
115 SARS-CoV-2 appear to have a high risk of fungal co-infections (Limper (Bodey et al. 1992; Limper
116 et al. 2017; Soltani et al. 2022). Strikingly, a sharp increase in deaths caused by fungal infection
117 was observed during the coronavirus disease pandemic (Gold et al. 2023). Widespread antifungal
118 resistance against commonly used drugs, particularly for *Candida auris*, worsens the current
119 threat of fungal infection (Pristov and Ghannoum 2019; Miramon et al. 2023). For infections
120 caused by Mucorales, drugs are generally insufficient, and radical surgical debridement is an
121 important but disfiguring treatment.

122 The fungi that cause invasive lethal infections in humans are spread throughout the fungal
123 kingdom, including members of the phyla Ascomycota (including *Candida albicans*, *C. auris*,
124 *Aspergillus fumigatus*, *Histoplasma capsulatum*, and *Pneumocystis jirovecii*), Basidiomycota
125 (*Cryptococcus neoformans*), and Mucoromycota (*Rhizopus arrhizus* a.k.a. *R. oryzae*). In previous
126 studies, Trl1 homologs from the human ascomycete pathogens *C. albicans*, *A. fumigatus*, and
127 *Coccidioides immitis* have been shown to complement *S. cerevisiae trl1Δ* strain (Remus et al.
128 2016), supporting that Trl1 function is conserved and a good candidate for being targeted by
129 antifungal drugs.

130 In this study, we identified functional homologs of ScTrl1 in a broader range of human pathogenic
131 fungi species that represent diverse evolutionary relatedness. The Trl1 homologs that have been
132 shown to complement *trl1Δ* are all from other Ascomycete fungi. Here, we have identified 'typical'
133 Trl1 orthologs in Ascomycota, Basidiomycota, and Mucoromycota pathogens that have all three
134 heal and seal domains and are capable of complementing *trl1Δ*, supporting that Trl1 targeting
135 drugs might be broad-spectrum antifungals. Interestingly, we identified an 'atypical' Trl1 ortholog
136 in the order Mucorales (*R. arrhizus* and *Mucor circinelloides*). These Trl1 orthologs contain a Trl1
137 ligase domain, but lack CPD and kinase domains. These Mucorales Trl1 "sealing-only" orthologs
138 can functionally complement defects in the ligase domain of ScTrl1 but not *trl1Δ*. Using

140 orthologous mutation in the conserved nucleotide binding motif, we demonstrate that the sealing-
141 only Trl1 of Mucorales is mechanistically similar to ScTrl1. Finally, the sealing-only Trl1 of
142 Mucorales can perform the sealing step of *HAC1* mRNA splicing in yeast, indicating that both the
143 known functions of Trl1 are retained. This suggests that drugs that target the ligase domain are
144 likely to be broader-spectrum antifungals than those targeting the CPD or kinase domains. These
145 findings imply that the Mucorales use kinase and CPD enzymes in a heal and seal pathway that
146 are not orthologs to Trl1.

147

148 **Results**

149 **Most pathogenic fungi contain a typical Trl1 ortholog, except the Mucorales**

150 We sought to identify the orthologs of *S. cerevisiae* tRNA ligase (ScTrl1) in a diverse range of
151 pathogenic fungi species, with a focus on pathogens that cause invasive disease with high
152 morbidity and mortality. Two primary criteria were considered for identifying ScTrl1 orthologs: (a)
153 the sequence-level similarities among the fungal *TRL1* genes with ScTRL1, and (b) the presence
154 of three domains in the fungal *TRL1* genes. First, we compared the human pathogens that belong
155 to the phylum Ascomycota. The Ascomycota are subdivided in three subphyla that each include
156 important human pathogens. Among the subphylum Saccharomycotina, the genomes of two
157 important human pathogens, *C. albicans* and *C. auris* (causative agents of candidiasis), encode
158 'typical' Trl1 orthologs with all three catalytic domains and an overall sequence similarity to ScTrl1
159 of 59% and 55%, respectively. Two representative fungi of the subphylum Pezizomycotina, *A.
160 fumigatus* (causative agent of aspergillosis), and *H. capsulatum* (causative agent of
161 histoplasmosis) also contain ScTrl1 orthologs with overall sequence similarity of 54% and 55%,
162 respectively. Finally, the subphylum Taphrinomycotina includes one significant human pathogen,
163 *P. jirovecii*, and its genome encodes a typical Trl1 ortholog with 52% similarity to ScTrl1. Thus, the
164 genomes of all human pathogens within the ascomycetes encode a typical Trl1 ortholog. Within
165 the phylum Basidiomycota, *C. neoformans* is the most important human pathogen and its genome
166 encodes a ScTrl1 ortholog with 46% similarity to ScTrl1.

167 Strikingly, we could not identify a typical Trl1 ortholog in the genome of *Rhizopus* species, the
168 most important pathogen within the Mucoromycota (e.g *R. arrhizus*) or in closely related species
169 (e.g. *M. circinelloides*). Instead, the Trl1 orthologs in these species were much smaller and
170 appeared to consist of only a ligase domain [Figure 1A]. These ligase domains were highly similar
171 to that of ScTrl1 (55% and 49%). Similar sealing-only Trl1 homologs were encoded in other
172 genomes of the order Mucorales, and all of them show sequence similarity with the ligase domain
173 of ScTrl1. In contrast, in other Mucoromycota, we readily identified typical Trl1 orthologs that
174 contain all three domains, (e.g. *Rhizophagus irregularis*, overall 52% similar to ScTrl1). This
175 suggests that a typical Trl1 ortholog was present in the common ancestor of the Mucoromycota,
176 Basidiomycota and Ascomycota, but was shortened after divergence of the Mucorales from the
177 other fungi. Despite extensive searches, we were unable to identify any genes in the Mucorales
178 that were orthologous to the CPD and kinase domains of Trl1.

179 To confirm that the Trl1 orthologs from *Rhizopus* and *Mucor* were truncated, we analyzed their
180 gene structure by RNAseq. A re-analysis of publicly available RNAseq data confirms that
181 transcripts of *R. arrhizus* and *M. circinelloides* *TRL1* orthologs encode only the ligase domain. In
182 *M. circinelloides*, the ligase domain is encoded in a single exon that is not spliced with any other
183 exon. In *R. arrhizus*, the ligase domain is encoded by three exons that are spliced together, but
184 not to any other exons. In contrast, the four exons that encode the ligase domain of *R. irregularis*
185 Trl1 are clearly spliced together with additional exons that encode the kinase and CPD domains
186 [Figure 1B]. Overall our data suggest that most human fungal pathogens express a typical Trl1
187 ortholog, but the Mucorales instead express a 'sealing-only Trl1'.

188 **The Mucorales contain a small number of tRNA introns and other components of a heal
189 and seal tRNA splicing pathway**

190 We investigated several possible explanations for the absence of a typical Trl1 from the
191 Mucorales. First, we considered the possibility that a lack of tRNA introns in the Mucorales means
192 they do not need a typical Trl1. Although all eukaryotes are thought to have tRNA introns, the
193 proportion of tRNA genes that contain introns varies widely. We observed the same pattern when
194 focusing on human fungal pathogens [Figure 1C] [Supplementary Table 1]. Eukaryotic genomes
195 generally encode 42-50 distinct tRNAs (isodecoders) that each decode 1 to 4 different codons.

196 Each of these isodecoders can be encoded by a single tRNA gene or by multiple tRNA genes. If
197 an isodecoder is encoded by multiple genes, typically either all of the genes for that isodecoder
198 contain an intron, or none of them do. Among the fungal pathogens analyzed, we saw similar
199 patterns, with *C. neoformans* containing the largest number of tRNA introns (92% of its tRNA
200 genes). In contrast, *R. arrhizus* and *M. circinelloides* contain a relatively small number of intron-
201 containing tRNAs (3% and 4% of its tRNA genes, respectively). Further analysis of isodecoder
202 tRNAs in fungal pathogens revealed that all of the genes for tyrosine tRNA (which decodes both
203 UAU and UAC) and for AUA isoleucine codons (but not AUU and AUC Ile codons) had an intron.
204 Thus *R. arrhizus* and *M. circinelloides* require tRNA splicing to decode three of the 61 sense
205 codons. While the genes for these same tRNAs contained introns in all fungal human pathogens,
206 there was a wide variation in the number of other intron-containing tRNA isodecoders and genes
207 [Figure 1C]. These observations rule out the possibility that the Mucorales do not need a typical
208 Trl1 because they might lack tRNA introns.
209

210 The tRNA splicing endonuclease (TSEN) complex mediates the endonuclease cleavage of the
211 intron-containing tRNA and comprises two catalytic subunits (Sen2 and Sen34) and two structural
212 subunits (Sen15 and Sen54). The two catalytic subunits are more highly conserved at the
213 sequence level, and we readily identified orthologs of both in the genome of all the major invasive
214 fungal pathogens, including *R. arrhizus* and *M. circinelloides* [Supplementary Table 2]. The
215 presence of both tRNA introns and a tRNA splicing endonuclease in the Mucorales strongly
216 suggest that they must contain a fully functional tRNA splicing pathway.
217

218 One possible explanation for the absence of a three-domain Trl1 is that Mucorales acquired an
219 RTCB-like ligase. We therefore searched their genomes but failed to detect any RTCB homologs.
220 A third ligase (C12orf29) has recently been identified in humans and suggested to possibly
221 function in tRNA splicing (Yuan et al. 2023), but we could not find any orthologs in the Mucorales
222 genomes.
223

224 If the Mucorales indeed use the truncated Trl1 in a heal and seal tRNA splicing pathway, they
225 should have homologs of Tpt1, the enzyme that removes the 2' phosphate left after the sealing
226 step. Indeed, the genomes of the Mucorales each include an obvious Tpt1 ortholog
227 [Supplementary Table 2]. The most likely explanation of these bio-informatic analyses is that the
228 Mucorales have functionally replaced the “healing” domains of Trl1 with an non-orthologous CPD
229 and kinase. Similar replacements have previously been artificially achieved in *S. cerevisiae* (see
230 discussion), but to the best of our knowledge has not been reported naturally.
231

232 **The sequence and predicted structure of sealing-only Trl1s of Mucorales suggest they are 233 functional RNA ligases**

234 The shorter tRNA ligase candidates of *R. arrhizus* and *M. circinelloides* contain 376 and 372
235 amino acids, respectively. Previous studies have identified that the N-terminal ligase domain of
236 Trl1 orthologs contains six conserved peptide motifs (I, Ia, III, IIIa, IV, and V) that are found in the
237 nucleotide-binding pocket (Wang and Shuman 2005). An amino acid sequence alignment reveals
238 that these conserved motifs are present in *R. arrhizus* and *M. circinelloides* and therefore
239 suggests that these proteins encode functional RNA ligases. [Supplementary Figure 1].

240 To gain insights into the structural features of Mucorales Trl1, we generated predicted structures
241 of *R. arrhizus* and *M. circinelloides* Trl1 using both AlphaFold2 (Varadi et al. 2022) and Phyre tools
242 (Kelley et al. 2015) [Figure 2 A-E]. Notably, although these tools use different approaches to
243 predict structure, they give very similar results with high confidence. The predicted structures
244 obtained from the analyses indicate that both Mucorales Trl1s share high structural similarities

245 with the ligase domain of the available X-ray structure of the Ascomycete fungus *Chaetomium*
246 *thermophilum* Trl1 (PDB: 6N0V, 6N0T, and 6N67) [Figure 2 A-C] (Banerjee et al. 2019; Peschek
247 and Walter 2019). The secondary structures predicted by AlphaFold2 of the N-terminal subdomain
248 of Mucorales Trl1 were superimposed with *C. thermophilum* Trl1 using the Matchmaker tool of
249 Chimera [Figure 2 D-E]. The overall architecture and the catalytic pocket, including the conserved
250 motifs, is conserved. The only notable difference in the N-terminal subdomains is a small N-
251 terminal extension (~30 amino acid residues) on the *C. thermophilum* protein that is distant from
252 the catalytic pocket and unlikely to alter the function. The C-terminal subdomain of Mucorales Trl1
253 also shows high structural similarity to the *C. thermophilum* X-ray structure. In *C. thermophilum*,
254 this domain consists of four alpha helices, and all four are conserved in the AlphaFold predicted
255 Mucorales structures. The only notable difference between the AlphaFold2 predictions and the *C.*
256 *thermophilum* structures is that AlphaFold2 predicts two short antiparallel beta strands inserted
257 between the second and third alpha helix of the C-terminal subdomain. These strands are distant
258 from the catalytic pocket and unlikely to alter the function of these proteins. Furthermore,
259 AlphaFold2 predicts that the N- and C-terminal subdomains are oriented very similar to those in
260 *C. thermophilum*.

261 To more objectively compare our AlphaFold2 predictions of *M. circinelloides* Trl1 and *R. arrhizus*
262 Trl1 to known structures, we performed a DALI search of the protein data bank (PDB). For *M.*
263 *circinelloides* and *R. arrhizus* Trl1, the top DALI recovered structure was the X-ray structure of the
264 ligase domain of the *C. thermophilum* (PDB 6N0V) with a z-score of 41.8 and 41.3, respectively
265 (Banerjee et al. 2019). The second most related structure from the DALI search was the X-ray
266 structure of T4 RNA Ligase (Rnl1) (PDB 2C5U) (El Omari et al. 2006). A key distinction between
267 Trl1 and T4 Rnl1 is that Trl1 uses a substrate with a 2'PO₄ 3'OH while T4 Rnl1 uses a substrate
268 with 2'OH 3'OH (Schwer et al. 2004; Banerjee et al. 2019). This biochemical difference is
269 mediated by a C-terminal extension on the Trl1 ligase domain (Banerjee et al. 2019). The 6N0T
270 structure identifies key residues that recognize the 2'PO₄ (N150, H227, R334 and R337), and
271 each of these residues is conserved in the *Rhizopus* and *Mucor* proteins and positioned in the
272 same place in the AlphaFold2 models. The R334 and R337 residues are part of a YRxxR motif in
273 the C-terminal subdomain, and the T4 Rnl1 C-terminal subdomain does not contain a similar
274 motif. The T4 Rnl1 subdomain is also positioned differently relative to the N-terminal subdomain
275 [Figure 2F]. Taken together, the predicted structures of Mucorales Trl1 suggest these proteins are
276 active RNA ligases that require a 2'PO₄.

277 The sealing-only Trl1s of Mucorales functionally complement the ScTrl1 ligase domain

278 In order to determine whether the Trl1 orthologs from invasive pathogenic fungi are functional, we
279 expressed Trl1 orthologs in a *S. cerevisiae* *trl1* Δ strain. A set of plasmid shuffle assays allowed
280 for the selection of the yeast cells that express fungal Trl1 orthologs and have lost the wild-type
281 ScTrl1 plasmids [Figure 3A]. Each of the tested three-domain containing 'typical fungal Trl1s' from
282 pathogenic fungi complemented *trl1* Δ . Specifically, replacing Trl1 with the Trl1 orthologs from the
283 closely related *C. albicans* and *C. auris* resulted in growth that resembled wild type. Complementation
284 with the ortholog of the more distantly related Ascomycota *A. fumigatus* or *H. capsulatum* also resulted
285 in growth, although at a reduced rate. We were unable to include *P. jirovecii* in this experiment because
286 this gene proved toxic during cloning in *E. coli*. This complementation by orthologs from other
287 Ascomycota confirms and extends previous reports (Remus et al. 2016). Remarkably, the full-length Trl1
288 orthologs from the Basidiomycota *C. neoformans* and the Mucoromycota *R. irregularis* can also complement
289 *trl1* Δ and resulted in near-normal growth rate. This indicates that all of the typical three-domain fungal Trl1s can perform
290 tRNA ligation in budding yeast. In contrast, as expected the truncated Trl1 orthologs from *R.*
291 *arrhizus* and *M. circinelloides* failed to complement *trl1* Δ and behaved similar to an empty vector
292 control.

294 We postulated that because the identified Mucorales Trl1s only contain the ligase domain, they
295 could only complement the exon ligation step (sealing step) but not the healing steps of the fungal
296 type tRNA splicing pathway. A conserved lysine residue in position 114 of ScTrl1 is required for
297 the function of the ligase domain. Amino acid change of the K114 residue to alanine (K114A)
298 exhibits defects in the sealing function of Trl1 and is lethal (Sawaya et al. 2003). We therefore
299 performed a plasmid shuffle assay to test whether Trl1 orthologs of pathogenic fungi can
300 functionally complement a ligase domain defect (*trl1-K114A*). As expected, all of the fungal Trl1
301 orthologs that complement *trl1Δ* also complemented *trl1-K114A*. Importantly, the sealing-only
302 Trl1s from Mucorales can complement this ligase-dead ScTrl1 [Figure 3B]. As expected, we
303 confirmed that the Mucorales Trl1s cannot perform the ‘healing’ reactions of tRNA splicing
304 pathway in budding yeast: they do not complement mutations in either the ScTrl1 kinase domain
305 (*trl1-K404AT405A*) or the CPD domain (*trl1-H777A*) [Figure 3C-D].

306 We examined whether the Mucorales Trl1s use the same catalytic lysine as ScTrl1. Sequence
307 alignment identified the corresponding conserved lysine residues as K116 for *R. arrhizus* and
308 K118 for *M. circinelloides*. A plasmid shuffle experiment indicates that changing these lysine
309 residues to alanine in either of the Mucorales proteins disrupted the ability to complement the
310 defect in the ScTrl1 ligase domain [Figure 3E]. Overall, these data indicate that Mucorales Trl1s
311 are functional tRNA ligases and are able to perform the tRNA sealing step but not the tRNA healing
312 steps.

313 **Mucorales Trl1 can perform *HAC1* mRNA splicing during the Unfolded Protein Response**

314 As discussed in the introduction, in addition to tRNA splicing, Trl1 takes part in the non-
315 conventional *HAC1* mRNA splicing mechanism during the Unfolded Protein Response (UPR) that
316 is initiated by Ire1. The UPR plays a critical role in the stress tolerance and virulence of pathogenic
317 fungi (Richie et al. 2009; Cheon et al. 2011; Askew 2014; Krishnan and Askew 2014). During
318 infection, fungal pathogens encounter several biotic and abiotic stresses in the host. Thus, an
319 increased protein folding capacity in the endoplasmic reticulum (ER) via UPR signaling is required
320 to overcome the host stresses associated with the increased pathogenicity of the fungal
321 pathogens.

322 The Mucorales genomes contain an obvious ortholog for Ire1, but Hac1 orthologs are poorly
323 conserved in sequence and difficult to detect across large evolutionary distance. Nevertheless,
324 we identified a likely Hac1 ortholog in *R. arrhizus* (hypothetical protein G6F37_009984;) and
325 RNAseq analysis identified an unannotated non-canonical intron [Figure 4A].

326 To test whether *R. arrhizus* and *M. circinelloides* Trl1 are able to perform *HAC1* mRNA splicing in
327 budding yeast, we repeated the plasmid shuffle assay in the sealing-defective ScTrl1 strain (*trl1-*
328 *K114A*) without or with 0.2µg/mL tunicamycin. Tunicamycin causes unfolded proteins to
329 accumulate in the ER; thus, the UPR is required for viability in the presence of 0.2µg/mL
330 tunicamycin. Indeed, *ire1Δ* and *ire1Δhac1Δ* control strains failed to grow in the presence of
331 tunicamycin. Importantly, the strains that express Trl1 from the Mucorales and a sealing-dead
332 ScTrl1 grew in the presence of tunicamycin and thus complemented the UPR defect [Figure 4B],
333 although the *M. circinelloides* ortholog performed better than the *R. arrhizus* ortholog. As a control,
334 the three-domain Trl1 from the Mucoromycota *R. irregularis* also complemented the UPR defect.

335 To confirm that growth on tunicamycin reflected the ability to splice *HAC1*, we assayed *HAC1*
336 mRNA splicing directly by RT-PCR with primers that span the intron [Figure 4C]. When the cells
337 were grown without UPR stress, the major RT-PCR product was the size expected for unspliced
338 *HAC1* mRNA. RT-PCR of the strains that express Mucoromycota Trl1s in addition to the ScTrl1
339 sealing-dead mutant resulted in a major product of 247 bp after UPR induction, reflecting removal
340 of the *HAC1* intron. The UPR defective *ire1Δ* strain used as a control produced only unspliced

341 *HAC1* mRNA. Taken together, these results indicate that *R. arrhizus* and *M. circinelloides* Trl1s
342 are able to carry out the sealing step of *HAC1* splicing during UPR stress when expressed in *S.*
343 *cerevisiae*.

344

345 **Discussion**

346 In this study we show that the tRNA ligase (Trl1) orthologs from a diverse range of clinically
347 relevant fungal pathogens are functionally conserved and can replace the Trl1 enzyme in *S.
348 cerevisiae*. These fungal species contain a subset of tRNA genes that require splicing to produce
349 functional tRNA molecules. Specifically, in each species the tRNA-Tyr-GUA and tRNA-Ile-UAU
350 tRNA genes contain an intron, while additional tRNA genes contain an intron in a subset of
351 pathogenic fungi. This indicates that tRNA splicing is essential in all invasive fungal human
352 pathogens. Alongside Trl1 orthologs, the presence of Tpt1 orthologs and the absence of
353 alternative ligases (RTCB or C12orf29 homologs) confirm that the 'healing and sealing'
354 mechanism is the prevalent mode of tRNA exon ligation in fungi. There is an urgent need for novel
355 antifungal drugs. There are very few enzymes that are essential across the fungal kingdom, but
356 absent in humans. The heal and seal pathway is a prominent exception and thus an attractive
357 target for antifungal drugs.

358 Pathogenic fungi including *A. fumigatus* and *C. neoformans* utilize the UPR to fine-tune protein
359 folding capacity in the ER, which is linked to virulence, membrane homeostasis, cell wall
360 homeostasis and anti-fungal drug resistance (Richie et al. 2009; Cheon et al. 2011; Askew 2014;
361 Krishnan and Askew 2014; Weichert et al. 2020). Thus, targeting the fungal UPR has been
362 suggested as a potential alternative strategy for antifungal development. The advantage of Trl1
363 as a drug target is that a Trl1 inhibitor would inhibit both tRNA splicing and the UPR in pathogenic
364 fungi.

365 Unlike other representative fungi, Mucorales (e.g. *R. arrhizus* and *M. circinelloides*) appear to
366 have separate sealing and healing enzymes to carry out tRNA exon ligation. Our identified Trl1
367 orthologs in Mucorales are functional ligases that can carry out the sealing reactions in both
368 known Trl1 functions: tRNA and *HAC1* mRNA splicing. However, the lack of the Trl1 kinase and
369 CPD domains in these orthologs suggests that they likely act with some other polynucleotide
370 kinase and phosphodiesterase that carry out the healing steps of tRNA and *HAC1* splicing. There
371 is precedence of this both in nature and in previous experiments. Englert et al. (2010) described
372 two Trl1 orthologs in the chordate *Branchiostoma floridae* (Florida lancelet) (Englert et al. 2010)
373 that are each truncated. One of the proteins contains only the sealing domains, while the other
374 contains the healing domains. The *B. floridae* genome also encodes RTCB and C12orf29
375 orthologs (XP_035676627 and XP_035678444). Which of these proteins splice the 42 annotated
376 tRNA introns in *B. floridae* (<http://gttadb.ucsc.edu/>) remains unknown. Despite extensive efforts,
377 we failed to detect proteins in the Mucorales that are orthologous to the healing domains of Trl1,
378 making the Mucorales distinct from *B. floridae*. Experimentally, the healing domains of Trl1 in
379 yeast can be replaced by the distantly related mammalian RNA 5'-kinase CLP1 and 2',3' cyclic
380 nucleotide phosphodiesterase (CNP) (Ramirez et al. 2008; Schwer et al. 2008). We propose that
381 the Mucorales similarly use distantly related healing enzymes in their healing and sealing
382 pathway, but the identity of these enzymes remains unknown. Because the Mucorales proteins
383 can seal the 2' PO₄ and 5' PO₄ ends generated by yeast healing domains, the unknown kinase
384 and CPD likely also generate 2' PO₄ and 5' PO₄ ends.

385 Our study supports the possibility of targeting the tRNA exon ligation mechanism for antifungal
386 development. The ligase domain of fungal Trl1 is conserved in all of the important invasive human
387 pathogens, including the Mucorales. Thus, a drug that inhibits the function of the Trl1 ligase
388 domain should be a broad-spectrum antifungal against these fungal pathogens. In contrast, drugs
389 that target the kinase and CPD domains are less likely to be effective against the Mucorales.
390 However, an antifungal that targets Ascomycete and Basidiomycete Trl1s would still be useful, as
391 these taxa include the most urgent fungal threats (<https://www.cdc.gov/drugresistance/biggest-threats.html>) and account for most of the cost of fungal infections (Benedict et al. 2019).

393 **Materials and methods**

394 **Identification of fungal Trl1 genes**

395 To identify Trl1 candidates in representative pathogenic fungi, extensive BLAST and PSI BLAST
396 searches were performed starting with either ScTrl1 or the *R. irregularis* ortholog. The *TRL1*
397 genes were identified based on the similarity of the domain composition and the sequence.
398 Orthologs of Sen2, Sen34, and Tpt1 were similarly identified with BLAST and PSI BLAST. The
399 search for alternative ligases used human RTCB, human C12ORF29, and *E. coli* RtcB protein
400 sequences.

401 To identify the correct exon junctions, publicly available RNA sequencing reads from *R. arrhizus*
402 strain 99-892 (SRR1013749 and SRR1013747), *M. circinelloides* strain R7B (SRR1611143,
403 SRR1611144, and SRR1611152), and *R. irregularis* (SRR14294959 and SRR14294960; (Dallaire
404 et al. 2021)) were aligned to the corresponding reference genome assemblies
405 (GCA_024220505.1, GCA_001638945.1, and GCF_000439145.1 (Tisserant et al. 2013),
406 respectively) using RNA STAR (Dobin et al. 2013).

407 tRNA annotations and their introns are from the genomic tRNA database
408 (<http://gtrnadb.ucsc.edu/index.html>); for species not included, they were identified using
409 tRNAscan-SE 2.0, the same algorithm used for the genomic tRNA database (Chan and Lowe
410 2016; Chan et al. 2021).

411 **Plasmids**

412 Plasmid used are listed in Supplemental table 3. Each of the *TRL1* orthologs was cloned into
413 p425GPD (Mumberg et al. 1995) using Gibson assembly. For *C. albicans* and *C. auris*, the single
414 exon genes were PCR amplified from genomic DNA (a kind gift from Michael Lorenz). For the
415 other species, we did not have ready access to genomic DNA or cDNA and therefore the *TRL1*
416 ORF was codon optimized for expression in *S. cerevisiae* and synthesized by GenScript.

417 The catalytic mutants for McirTRL1 (Mcir trl1-K118A) and RarrTRL1 (Rarr trl1-K116A) plasmids
418 were created using the QuikChange Lightning Site-Directed Mutagenesis Kit following
419 manufacturer's instructions.

420 The catalytic mutants for ScTRL1 (trl1-K114A, trl1-H777A and trl1-K404A-T405A) were generated
421 by Gibson assembly into pRS413 (Sikorski and Hieter 1989; Sawaya et al. 2003).

422 All plasmids were sequence verified either by sequencing the whole plasmid using nanopore
423 sequencing (Plasmidsaurus) or by sequencing the insert using Sanger sequencing (Genewiz).

424 **Complementation of fungal Trl1s in *trl1* Δ yeast**

425 The yeast strains used are listed in supplemental table 4. To identify whether the Trl1 of
426 representative fungi can complement the loss of ScTrl1, the corresponding *TRL1* expression
427 plasmids of fungi were transformed into *S. cerevisiae* *trl1* Δ [*TRL1*, *URA3*] strain. This parent strain
428 was created from the *S. cerevisiae* heterozygous knockout library by transforming *TRL1*, *URA3*
429 plasmid (pAV1511) and sporulating the transformants. The resulting strain was *matA*, *ura3* Δ 0 ,
430 *leu2* Δ 0 , *his3* Δ 1 , *lys2* Δ 0 , *trl1* Δ ::*NEO*, [*TRL1*,*URA3*] and unable to grow on 5-FOA-containing
431 media.

432 The transformants for yeast cells containing *TRL1* expression plasmids were selected in the SC
433 media lacking leucine and uracil (SC-Leu-Ura, Sunrise Science). A plasmid shuffle experiment
434 was performed, where the serially diluted yeast strains were spotted on 5-FOA-containing media

435 that selects for yeast cells that have lost the wild-type *ScTRL1*, *URA3* plasmid and contains only
436 the *TRL1* of corresponding fungi (Boeke et al. 1987). Growth was recorded after 4 days at 30°C.

437 To identify the ability of the fungal Trl1 to complement the defects in individual domain (LIG, KIN,
438 CPD) function of ScTrl1, the corresponding *TRL1* plasmids were transformed into *trl1Δ* strains
439 that contain sealing-dead, CPD-dead or kinase-dead Trl1s in pRS413 (CEN, *HIS3*) plasmids in
440 addition to the *TRL1* gene on a CEN, *URA3* plasmid. The transformants were selected on SC-
441 Leu-His media (Sunrise Science), and a plasmid shuffle assay was performed as described
442 above.

443 To identify the ability of the fungal Trl1 to complement the Trl1 function in the unfolded protein
444 response, *trl1Δ* yeast cells containing a *LEU2* plasmid expressing the *TRL1* of other fungi, a *HIS3*
445 plasmid expressing *Sc trl1-K114A* and a *URA3* plasmid expressing wild-type *ScTRL1* were
446 serially diluted and spotted on 5-FOA-containing media supplemented with or without 0.2 µg/mL
447 tunicamycin (Sigma-Aldrich). Growth was recorded after 4 days at 30°C. The control *ire1Δ* strain
448 was obtained from the knock out collection(Giaever et al. 2002). The control *ire1Δhac1Δ* strain
449 (YAv4415) was generated by standard genetic crosses of single mutants obtained from the knock
450 out collection. The *hac1Δ::KANMX* allele was converted to *hac1Δ::NATMX* using plasmid p4339
451 (obtained from Charles Boone).

452 RNA extraction and RT-PCR

453 Overnight cultures of yeast strains were diluted to ~0.1 OD₆₀₀ in YPD and grown to ~0.6 OD₆₀₀ at
454 30°C. UPR induction was carried out by adding 2.5 µg/mL tunicamycin for 2 hours. The cells were
455 harvested, and total RNA was extracted using the hot phenol method (He et al. 2008). The RNA
456 samples were treated with DNase I (Invitrogen), and cDNA was synthesized with SuperScript™
457 II Reverse Transcriptase (Invitrogen). The *HAC1* spliced and unspliced fragments were amplified
458 with intron-spanning primers (ACCTGCCGTAGACAACAACAAAT and
459 AAAACCCACCAACAGCGATAAT) and analyzed on a 2% agarose gel (Cherry et al. 2019).

460

461 **Acknowledgements**

462 This work was funded by National Institutes of Health (NIH) grant R35GM141710 to A.v.H. and a
463 Dr. John J. Kopchick Research grant from the UT MD Anderson Cancer Center UTHealth Houston
464 Graduate School of Biomedical Sciences to K.S.A. We thank Sean Johnson for help with
465 AlphaFold2 predictions and Michelle Steiger, Mike Lorenz, Sean Johnson , and members of the
466 van Hoof lab for insightful comments.

467

468 **Figure legends**

469

470 **Figure 1: The Mucorales contain an atypical Trl1 ortholog with only the “sealing” domain.**
471 **(A)** Domain architecture of *S. cerevisiae* Trl1 and orthologs from two Mucorales (*R. arrhizus* and
472 *M. circinelloides*). LIG; ligase domain, KIN; kinase domain, and CPD; cyclic phosphodiesterase
473 domain. **(B)** The tRNA ligase of *M. circinelloides* and *R. arrhizus* express as sealing-only single
474 domain Trl1s, whereas *R. irregularis* Trl1 contains three domains. Shown is RNA-seq read
475 coverage of the *TRL1* orthologs of *M. circinelloides*, *R. arrhizus* (both Mucorales) and the related
476 *R. irregularis* tRNA ligase. Colors reflect domains as in A. **(C)** The Mucorales contain a minimal
477 set of intron-containing tRNAs. The number of intronless isodecoders (white), intron-containing
478 isodecoders (grey), and intron-containing Tyr GUA (decoding UAC and UAU codons) and Ile UAU
479 (decoding AUA codons) (dark grey) isodecoders in the genomes of major pathogenic fungi is
480 shown.

481

482 **Figure 2: The predicted structures of Mucorales Trl1 resemble the ligase domain of fungal**
483 **tRNA ligase.** **(A)** X-ray crystal structure of the ligase domain of the ascomycete fungus *C.*
484 *thermophilum* (6N0T). **B** The AlphaFold predicted structure of *R. arrhizus* sealing-only Trl1. **(B)**
485 The AlphaFold predicted structure of *M. circinelloides* sealing-only Trl1. **(D)** Superimposition of X-
486 ray crystal and AlphaFold predicted structures from A to C. Colors are as in A to C. For *R. arrhizus*
487 RMSD is .913Å over 247 C α atoms for *M. circinelloides* it is .901Å over 244 C α atoms **(E)**
488 Superimposition of X-ray crystal and Phyre predicted structures. Colors are as in A to C. **F**
489 Superimposition of X-ray crystal structures of Trl1 ligase from *C. thermophilum* (6N0T) and T4
490 RNA ligase (2C5U; plum colored). The N- and C-terminal subdomains are indicated in each panel.

491

492 **Figure 3: Complementation of Trl1 defects by orthologs from fungal pathogens.** **(A)** The
493 Trl1 orthologs of representative pathogenic fungi complement *trl1* Δ , except the sealing-only Trl1s
494 of Mucorales. The indicated Trl1 orthologs were expressed in *S. cerevisiae* *trl1* Δ [*TRL1*, *URA3*]
495 strain background and subjected to serial dilution growth assay on media containing 5-FOA
496 (selecting against the *TRL1* plasmid) or control media. **(B-D)** The Mucorales Trl1 can complement
497 a defect in the ligase (LIG) domain of ScTrl1 (B) but is unable to complement the defects in the
498 kinase (KIN; C) or cyclic phosphodiesterase (CPD; D) domain of ScTrl1. The indicated Trl1
499 orthologs were expressed in a strain that contains a *URA3* plasmid with a wild-type *TRL1* gene
500 and another plasmid with either the sealing-defective *trl1*-K114A (B), the kinase-defective
501 *trl1*-K404AT405A (C), or the cyclic phosphodiesterase-defective *trl1*-H777A (D) subjected to serial
502 dilution growth assay on media containing 5-FOA (selecting against the *TRL1* plasmid) or control
503 media. **(E)** A conserved lysine in the active site is critical in the Mucorales Trl1s. Amino acid
504 changes orthologous to scTrl1-K114A were introduced in Mucorales Trl1 and subjected to plasmid
505 shuffle assay in the sealing-defective ScTrl1 strain as in B.

506

507 **Figure 4: Mucorales sealing-only Trl1s can perform *HAC1* splicing during the Unfolded**
508 **Protein Response (UPR).** **(A)** *R. arrhizus* appears to have an Ire-dependent intron in *HAC1*
509 mRNA (encoding the 149 amino acid hypothetical protein G6F37_009984). Sequence similarity
510 to Hac1 is highest in the indicated bZIP domain. Depicted is the unspliced (RaHAC1 u) and spliced
511 (RaHAC1 s) mRNA structure based on aligning RNAseq data (SRR1013749) to the genome with
512 RNA STAR, and the predicted function of Ire1 and sealing-only Trl1 in generating spliced *HAC1*
513 mRNA. **(B)** The *M. circinelloides*, *R. arrhizus*, and *R. irregularis* Trl1 were expressed in *S.*

514 *cerevisiae* *trl1Δ* [*trl1-K114A*] [*TRL1, URA3*] strain background and subjected to plasmid shuffle
515 assay in the presence or absence of 0.2 µg/mL tunicamycin. The wild-type (WT), *ire1Δhac1Δ*,
516 and *ire1Δ* strains were used as a control. (C) RT-PCR of *HAC1* indicates that upon UPR induction,
517 the Mucorales *Trl1* gives rise to spliced *HAC1* mRNA (*HAC1^S*). The *HAC1* splicing defective *ire1Δ*
518 strain was used as a control, which only produced the unspliced *HAC1* mRNA (*HAC1^U*).

519

520

521

522 Abelson J, Trotta CR, Li H. 1998. tRNA splicing. *The Journal of biological chemistry* **273**: 12685-12688.

523 Amitsur M, Levitz R, Kaufmann G. 1987. Bacteriophage T4 anticodon nuclease, polynucleotide kinase
524 and RNA ligase reprocess the host lysine tRNA. *EMBO J* **6**: 2499-2503.

525 Askew DS. 2014. Endoplasmic reticulum stress and fungal pathogenesis converge. *Virulence* **5**: 331-333.

526 Banerjee A, Ghosh S, Goldgur Y, Shuman S. 2019. Structure and two-metal mechanism of fungal tRNA
527 ligase. *Nucleic Acids Res* **47**: 1428-1439.

528 Benedict K, Jackson BR, Chiller T, Beer KD. 2019. Estimation of Direct Healthcare Costs of Fungal Diseases
529 in the United States. *Clin Infect Dis* **68**: 1791-1797.

530 Bodey G, Buelmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S
531 et al. 1992. Fungal infections in cancer patients: an international autopsy survey. *Eur J Clin
532 Microbiol Infect Dis* **11**: 99-109.

533 Boeke JD, Trueheart J, Natsoulis G, Fink GR. 1987. 5-Fluoroorotic acid as a selective agent in yeast
534 molecular genetics. *Methods Enzymol* **154**: 164-175.

535 Braun BR, van Het Hoog M, d'Enfert C, Martchenko M, Dungan J, Kuo A, Inglis DO, Uhl MA, Hogues H,
536 Berriman M et al. 2005. A human-curated annotation of the *Candida albicans* genome. *PLoS
537 Genet* **1**: 36-57.

538 Chakravarty AK, Subbotin R, Chait BT, Shuman S. 2012. RNA ligase RtcB splices 3'-phosphate and 5'-OH
539 ends via covalent RtcB-(histidinyl)-GMP and polynucleotide-(3')pp(5')G intermediates. *Proc Natl
540 Acad Sci U S A* **109**: 6072-6077.

541 Chan PP, Lin BY, Mak AJ, Lowe TM. 2021. tRNAscan-SE 2.0: improved detection and functional
542 classification of transfer RNA genes. *Nucleic Acids Res* **49**: 9077-9096.

543 Chan PP, Lowe TM. 2016. GtRNAdb 2.0: an expanded database of transfer RNA genes identified in
544 complete and draft genomes. *Nucleic Acids Res* **44**: D184-189.

545 Chen X, Wolin SL. 2023. Transfer RNA halves are found as nicked tRNAs in cells: evidence that nicked
546 tRNAs regulate expression of an RNA repair operon. *RNA* **29**: 620-629.

547 Cheon SA, Jung KW, Chen YL, Heitman J, Bahn YS, Kang HA. 2011. Unique evolution of the UPR pathway
548 with a novel bZIP transcription factor, Hxl1, for controlling pathogenicity of *Cryptococcus
549 neoformans*. *PLoS Pathog* **7**: e1002177.

550 Dallaire A, Manley BF, Wilkens M, Bista I, Quan C, Evangelisti E, Bradshaw CR, Ramakrishna NB,
551 Schornack S, Butter F et al. 2021. Transcriptional activity and epigenetic regulation of
552 transposable elements in the symbiotic fungus *Rhizophagus irregularis*. *Genome Res* **31**: 2290-
553 2302.

554 Desai KK, Bingman CA, Phillips GN, Jr., Raines RT. 2013. Structures of the noncanonical RNA ligase RtcB
555 reveal the mechanism of histidine guanylylation. *Biochemistry* **52**: 2518-2525.

556 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013.
557 STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**: 15-21.

558 Englert M, Sheppard K, Gundlapalli S, Beier H, Soll D. 2010. *Branchiostoma floridae* has separate healing
559 and sealing enzymes for 5'-phosphate RNA ligation. *Proc Natl Acad Sci U S A* **107**: 16834-16839.

560 Englert M, Xia S, Okada C, Nakamura A, Tanavde V, Yao M, Eom SH, Konigsberg WH, Soll D, Wang J. 2012.
561 Structural and mechanistic insights into guanylylation of RNA-splicing ligase RtcB joining RNA
562 between 3'-terminal phosphate and 5'-OH. *Proc Natl Acad Sci U S A* **109**: 15235-15240.

563 Garber G. 2001. An overview of fungal infections. *Drugs* **61 Suppl 1**: 1-12.

564 Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, Dow S, Lucau-Danila A, Anderson K, Andre B et
565 al. 2002. Functional profiling of the *Saccharomyces cerevisiae* genome. *Nature* **418**: 387-391.

566 Gold JAW, Ahmad FB, Cisewski JA, Rossen LM, Montero AJ, Benedict K, Jackson BR, Toda M. 2023.
567 Increased Deaths From Fungal Infections During the Coronavirus Disease 2019 Pandemic-

National Vital Statistics System, United States, January 2020-December 2021. *Clin Infect Dis* **76**: e255-e262.

Gonzalez TN, Sidrauski C, Dorfler S, Walter P. 1999. Mechanism of non-spliceosomal mRNA splicing in the unfolded protein response pathway. *EMBO J* **18**: 3119-3132.

Greer CL, Peebles CL, Gegenheimer P, Abelson J. 1983. Mechanism of action of a yeast RNA ligase in tRNA splicing. *Cell* **32**: 537-546.

Hayne CK, Sekulovski S, Hurtig JE, Stanley RE, Trowitzsch S, van Hoof A. 2023. New insights into RNA processing by the eukaryotic tRNA splicing endonuclease. *The Journal of biological chemistry* **299**: 105138.

Jacewicz A, Dantuluri S, Shuman S. 2022. Structures of RNA ligase RtcB in complexes with divalent cations and GTP. *RNA* **28**: 1509-1518.

Kainz K, Bauer MA, Madeo F, Carmona-Gutierrez D. 2020. Fungal infections in humans: the silent crisis. *Microb Cell* **7**: 143-145.

Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. 2015. The Phyre2 web portal for protein modeling, prediction and analysis. *Nat Protoc* **10**: 845-858.

Konarska M, Filipowicz W, Domdey H, Gross HJ. 1981. Formation of a 2'-phosphomonoester, 3',5'-phosphodiester linkage by a novel RNA ligase in wheat germ. *Nature* **293**: 112-116.

Kosmaczewski SG, Edwards TJ, Han SM, Eckwahl MJ, Meyer BI, Peach S, Hesselberth JR, Wolin SL, Hammarlund M. 2014. The RtcB RNA ligase is an essential component of the metazoan unfolded protein response. *EMBO Rep* **15**: 1278-1285.

Krishnan K, Askew DS. 2014. The fungal UPR: a regulatory hub for virulence traits in the mold pathogen *Aspergillus fumigatus*. *Virulence* **5**: 334-340.

Limper AH, Adenis A, Le T, Harrison TS. 2017. Fungal infections in HIV/AIDS. *Lancet Infect Dis* **17**: e334-e343.

Liu M, Healy MD, Dougherty BA, Esposito KM, Maurice TC, Mazzucco CE, Brucolieri RE, Davison DB, Frosco M, Barrett JF et al. 2006. Conserved fungal genes as potential targets for broad-spectrum antifungal drug discovery. *Eukaryot Cell* **5**: 638-649.

Lopes RR, Kessler AC, Polycarpo C, Alfonzo JD. 2015. Cutting, dicing, healing and sealing: the molecular surgery of tRNA. *Wiley Interdiscip Rev RNA* **6**: 337-349.

Lu Y, Liang FX, Wang X. 2014. A synthetic biology approach identifies the mammalian UPR RNA ligase RtcB. *Mol Cell* **55**: 758-770.

Miramonti P, Pountain AW, Lorenz MC. 2023. *Candida auris*-macrophage cellular interactions and transcriptional response. *Infect Immun*: e0027423.

Mori K. 2009. Signalling pathways in the unfolded protein response: development from yeast to mammals. *J Biochem* **146**: 743-750.

Mumberg D, Muller R, Funk M. 1995. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. *Gene* **156**: 119-122.

Nandy A, Saenz-Mendez P, Gorman AM, Samali A, Eriksson LA. 2017. Homology model of the human tRNA splicing ligase RtcB. *Proteins* **85**: 1983-1993.

Peebles CL, Gegenheimer P, Abelson J. 1983. Precise excision of intervening sequences from precursor tRNAs by a membrane-associated yeast endonuclease. *Cell* **32**: 525-536.

Peebles CL, Ogden RC, Knapp G, Abelson J. 1979. Splicing of yeast tRNA precursors: a two-stage reaction. *Cell* **18**: 27-35.

Peschek J, Walter P. 2019. tRNA ligase structure reveals kinetic competition between non-conventional mRNA splicing and mRNA decay. *Elife* **8**.

Phizicky EM, Hopper AK. 2023. The life and times of a tRNA. *RNA* **29**: 898-957.

Phizicky EM, Schwartz RC, Abelson J. 1986. *Saccharomyces cerevisiae* tRNA ligase. Purification of the protein and isolation of the structural gene. *The Journal of biological chemistry* **261**: 2978-2986.

616 Popow J, Englert M, Weitzer S, Schleiffer A, Mierzwa B, Mechtler K, Trowitzsch S, Will CL, Luhrmann R,
617 Soll D et al. 2011. HSPC117 is the essential subunit of a human tRNA splicing ligase complex.
618 *Science* **331**: 760-764.

619 Popow J, Schleiffer A, Martinez J. 2012. Diversity and roles of (t)RNA ligases. *Cell Mol Life Sci* **69**: 2657-
620 2670.

621 Pristov KE, Ghannoum MA. 2019. Resistance of Candida to azoles and echinocandins worldwide. *Clin
622 Microbiol Infect* **25**: 792-798.

623 Ramirez A, Shuman S, Schwer B. 2008. Human RNA 5'-kinase (hClp1) can function as a tRNA splicing
624 enzyme in vivo. *RNA* **14**: 1737-1745.

625 Reddy GKK, Padmavathi AR, Nanchariah YV. 2022. Fungal infections: Pathogenesis, antifungals and
626 alternate treatment approaches. *Curr Res Microb Sci* **3**: 100137.

627 Remus BS, Schwer B, Shuman S. 2016. Characterization of the tRNA ligases of pathogenic fungi
628 *Aspergillus fumigatus* and *Coccidioides immitis*. *RNA* **22**: 1500-1509.

629 Richie DL, Hartl L, Aimananda V, Winters MS, Fuller KK, Miley MD, White S, McCarthy JW, Latge JP,
630 Feldmesser M et al. 2009. A role for the unfolded protein response (UPR) in virulence and
631 antifungal susceptibility in *Aspergillus fumigatus*. *PLoS Pathog* **5**: e1000258.

632 Sawaya R, Schwer B, Shuman S. 2003. Genetic and biochemical analysis of the functional domains of
633 yeast tRNA ligase. *The Journal of biological chemistry* **278**: 43928-43938.

634 Schwer B, Aronova A, Ramirez A, Braun P, Shuman S. 2008. Mammalian 2',3' cyclic nucleotide
635 phosphodiesterase (CNP) can function as a tRNA splicing enzyme in vivo. *RNA* **14**: 204-210.

636 Schwer B, Sawaya R, Ho CK, Shuman S. 2004. Portability and fidelity of RNA-repair systems. *Proc Natl
637 Acad Sci U S A* **101**: 2788-2793.

638 Shuman S. 2023. RNA Repair: Hiding in Plain Sight. *Annu Rev Genet*.

639 Sidrauski C, Cox JS, Walter P. 1996. tRNA ligase is required for regulated mRNA splicing in the unfolded
640 protein response. *Cell* **87**: 405-413.

641 Sikorski RS, Hieter P. 1989. A system of shuttle vectors and yeast host strains designed for efficient
642 manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* **122**: 19-27.

643 Soltani S, Zandi M, Faramarzi S, Shahbahrami R, Vali M, Rezayat SA, Pakzad R, Malekifar P, Pakzad I,
644 Jahandoost N et al. 2022. Worldwide prevalence of fungal coinfections among COVID-19
645 patients: a comprehensive systematic review and meta-analysis. *Osong Public Health Res
646 Perspect* **13**: 15-23.

647 Spinelli SL, Consaul SA, Phizicky EM. 1997. A conditional lethal yeast phosphotransferase (tpt1) mutant
648 accumulates tRNAs with a 2'-phosphate and an undermodified base at the splice junction. *RNA*
649 **3**: 1388-1400.

650 Steiger MA, Kierzak R, Turner DH, Phizicky EM. 2001. Substrate recognition by a yeast 2'-
651 phosphotransferase involved in tRNA splicing and by its *Escherichia coli* homolog. *Biochemistry*
652 **40**: 14098-14105.

653 Tanaka N, Meineke B, Shuman S. 2011. RtcB, a novel RNA ligase, can catalyze tRNA splicing and HAC1
654 mRNA splicing in vivo. *J Biol Chem* **286**: 30253-30257.

655 Tanaka N, Shuman S. 2011. RtcB is the RNA ligase component of an *Escherichia coli* RNA repair operon. *J
656 Biol Chem* **286**: 7727-7731.

657 Tisserant E, Malbreil M, Kuo A, Kohler A, Symeonidi A, Balestrini R, Charron P, Duensing N, Frei dit Frey N,
658 Gianinazzi-Pearson V et al. 2013. Genome of an arbuscular mycorrhizal fungus provides insight
659 into the oldest plant symbiosis. *Proc Natl Acad Sci U S A* **110**: 20117-20122.

660 Vallabhaneni S, Baggs J, Tsay S, Srinivasan AR, Jernigan JA, Jackson BR. 2018. Trends in antifungal use in
661 US hospitals, 2006-12. *J Antimicrob Chemother* **73**: 2867-2875.

662 Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A
663 et al. 2022. AlphaFold Protein Structure Database: massively expanding the structural coverage
664 of protein-sequence space with high-accuracy models. *Nucleic Acids Res* **50**: D439-D444.

665 von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely OA, Kurzai O. 2019. Invasive Fungal Infection. *Dtsch
666 Arztebl Int* **116**: 271-278.

667 Wang LK, Schwer B, Englert M, Beier H, Shuman S. 2006. Structure-function analysis of the kinase-CPD
668 domain of yeast tRNA ligase (Trl1) and requirements for complementation of tRNA splicing by a
669 plant Trl1 homolog. *Nucleic Acids Res* **34**: 517-527.

670 Wang LK, Shuman S. 2005. Structure-function analysis of yeast tRNA ligase. *RNA* **11**: 966-975.

671 Weichert M, Guirao-Abad J, Aimananda V, Krishnan K, Grisham C, Snyder P, Sheehan A, Abbu RR, Liu H,
672 Filler SG et al. 2020. Functional Coupling between the Unfolded Protein Response and
673 Endoplasmic Reticulum/Golgi Ca(2+)-ATPases Promotes Stress Tolerance, Cell Wall Biosynthesis,
674 and Virulence of *Aspergillus fumigatus*. *mBio* **11**.

675 Yuan Y, Stumpf FM, Schlor LA, Schmidt OP, Saumer P, Huber LB, Frese M, Hollmuller E, Scheffner M,
676 Stengel F et al. 2023. Chemoproteomic discovery of a human RNA ligase. *Nat Commun* **14**: 842.

677







